Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks SNK01 given intravenously (IV) appears to cross...
October 24, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023 NKGen’s SNK01 program continues to show positive...
October 19, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SANTA ANA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
October 17, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

SANTA ANA, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
October 11, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

SANTA ANA, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
October 02, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Biotech, Inc. Announces Closing of Business Combination

SANTA ANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
September 21, 2023 14:15 ET | Source: NKGen Biotech, Inc.

NKGen Biotech to Present at the Cantor Fitzgerald Global Healthcare Conference 2023

SANTA ANA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
August 30, 2023 07:00 ET | Source: NKGen Biotech, Inc.

Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without...
August 24, 2023 08:00 ET | Source: NKGen Biotech, Inc.

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
August 15, 2023 12:07 ET | Source: NKGen Biotech, Inc.

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination

Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company’s Securities to be Listed on Nasdaq Under Ticker Symbols “NKGN”...